UKONIQ - (200MG ; Tablet)

Generic Name	UMBRALISIB TOSYLATE	**Innovator**	TG THERAPS
Dosage	200MG ; Tablet	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	UKONIQ is a kinase inhibitor indicated for the treatment of adult patients with: • Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen. • Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.